Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
2.400
+0.010 (0.42%)
Sep 16, 2025, 3:38 PM EDT - Market open

Annovis Bio Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202017 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Net Income
-30.26-24.59-56.2-25.33-14.49-5.46
Upgrade
Other Amortization
-----0
Upgrade
Stock-Based Compensation
2.873.844.639.154.71.86
Upgrade
Other Operating Activities
7.22-1.8211.84--0.03
Upgrade
Change in Accounts Payable
-2.421.01-2.673.270.35-0.7
Upgrade
Change in Other Net Operating Assets
-2.11-0.332.44-4.410.310.29
Upgrade
Operating Cash Flow
-24.69-21.89-39.97-17.31-9.13-3.97
Upgrade
Issuance of Common Stock
37.8226.6917.34046.7412.04
Upgrade
Financing Cash Flow
37.8226.6917.34046.7412.04
Upgrade
Net Cash Flow
13.134.8-22.62-17.3137.618.07
Upgrade
Levered Free Cash Flow
-16.45-12.17-23.75-7.93-3.73-3.02
Upgrade
Unlevered Free Cash Flow
-16.45-12.17-23.75-7.93-3.73-3.02
Upgrade
Change in Working Capital
-4.530.68-0.23-1.140.66-0.4
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q